Compare Stocks: DRUG, XERS, CMPS, and OCUL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPS Compass Pathways	$12.96 -2.0%	$13.37	$4.88 ▼ $15.87	$1.83B	2.54	2.72 million shs	2.50 million shs
DRUG Bright Minds Biosciences	$49.74 -3.7%	$70.28	$48.94 ▼ $123.75	$502.76M	-5.36	88,481 shs	96,756 shs
OCUL Ocular Therapeutix	$7.87 +2.7%	$9.88	$6.23 ▼ $16.44	$1.68B	0.97	2.84 million shs	5.28 million shs
XERS Xeris Biopharma	$9.98 +1.5%	$8.41	$5.25 ▼ $11.33	$1.79B	0.7	2.01 million shs	19.29 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPS Compass Pathways	-2.04%	-12.31%	-5.61%	-2.48%	+120.78%
DRUG Bright Minds Biosciences	-3.72%	-18.02%	-31.69%	-25.25%	-13.42%
OCUL Ocular Therapeutix	+2.74%	-25.05%	-24.03%	-16.90%	-37.19%
XERS Xeris Biopharma	+1.53%	+14.32%	+17.69%	+24.75%	+23.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPS Compass Pathways	$12.96 -2.0%	$13.37	$4.88 ▼ $15.87	$1.83B	2.54	2.72 million shs	2.50 million shs
DRUG Bright Minds Biosciences	$49.74 -3.7%	$70.28	$48.94 ▼ $123.75	$502.76M	-5.36	88,481 shs	96,756 shs
OCUL Ocular Therapeutix	$7.87 +2.7%	$9.88	$6.23 ▼ $16.44	$1.68B	0.97	2.84 million shs	5.28 million shs
XERS Xeris Biopharma	$9.98 +1.5%	$8.41	$5.25 ▼ $11.33	$1.79B	0.7	2.01 million shs	19.29 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPS Compass Pathways	-2.04%	-12.31%	-5.61%	-2.48%	+120.78%
DRUG Bright Minds Biosciences	-3.72%	-18.02%	-31.69%	-25.25%	-13.42%
OCUL Ocular Therapeutix	+2.74%	-25.05%	-24.03%	-16.90%	-37.19%
XERS Xeris Biopharma	+1.53%	+14.32%	+17.69%	+24.75%	+23.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPS Compass Pathways	2.88	Moderate Buy	$23.36	80.22% Upside
DRUG Bright Minds Biosciences	2.78	Moderate Buy	$143.83	189.17% Upside
OCUL Ocular Therapeutix	2.77	Moderate Buy	$25.75	227.19% Upside
XERS Xeris Biopharma	2.43	Hold	$12.80	28.26% Upside

Current Analyst Ratings Breakdown

Latest DRUG, XERS, CMPS, and OCUL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/29/2026	OCUL Ocular Therapeutix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/29/2026	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00
9/16/2026	OCUL Ocular Therapeutix	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
9/16/2026	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/15/2026	DRUG Bright Minds Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/10/2026	XERS Xeris Biopharma	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$12.00 ➝ $16.00
9/9/2026	CMPS Compass Pathways	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	DRUG Bright Minds Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Market Perform
8/20/2026	DRUG Bright Minds Biosciences	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	XERS Xeris Biopharma	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$9.00 ➝ $12.00
8/19/2026	DRUG Bright Minds Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$145.00

(Data available from 9/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPS Compass Pathways	N/A	N/A	N/A	N/A	($0.55) per share	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$8.33 per share	N/A
OCUL Ocular Therapeutix	$51.95M	33.27	N/A	N/A	$3.07 per share	2.56
XERS Xeris Biopharma	$335.41M	5.42	$0.10 per share	98.14	$0.08 per share	124.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPS Compass Pathways	-$287.86M	-$4.62	N/A	N/A	N/A	N/A	-49.63%	-13.08%	11/3/2026 (Estimated)
DRUG Bright Minds Biosciences	-$8.74M	-$2.08	N/A	N/A	N/A	N/A	-12.46%	-12.30%	N/A
OCUL Ocular Therapeutix	-$265.94M	-$1.42	N/A	N/A	N/A	-579.10%	-59.89%	-45.99%	11/3/2026 (Estimated)
XERS Xeris Biopharma	$550K	-$0.11	N/A	33.27	N/A	-5.12%	338.21%	3.50%	11/5/2026 (Estimated)

Latest DRUG, XERS, CMPS, and OCUL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/17/2026	Q3 2026	DRUG Bright Minds Biosciences	-$1.2230	-$0.17	+$1.0530	-$0.17	N/A	N/A
8/6/2026	Q2 2026	XERS Xeris Biopharma	$0.0121	-$0.18	-$0.1921	-$0.18	$90.13 million	$92.10 million
8/5/2026	Q2 2026	CMPS Compass Pathways	-$0.3881	-$1.88	-$1.4919	-$1.88	N/A	N/A
8/3/2026	Q2 2026	OCUL Ocular Therapeutix	-$0.3955	-$0.35	+$0.0455	-$0.35	$13.20 million	$13.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPS Compass Pathways	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPS Compass Pathways	0.60	1.30	1.30
DRUG Bright Minds Biosciences	N/A	122.00	122.00
OCUL Ocular Therapeutix	0.14	13.10	13.03
XERS Xeris Biopharma	17.00	1.45	1.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPS Compass Pathways	46.19%
DRUG Bright Minds Biosciences	40.52%
OCUL Ocular Therapeutix	59.21%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
CMPS Compass Pathways	2.82%
DRUG Bright Minds Biosciences	42.66%
OCUL Ocular Therapeutix	3.10%
XERS Xeris Biopharma	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPS Compass Pathways	156	138.48 million	134.57 million	Optionable
DRUG Bright Minds Biosciences	25	9.73 million	5.58 million	Not Optionable
OCUL Ocular Therapeutix	325	219.62 million	212.81 million	Optionable
XERS Xeris Biopharma	435	182.32 million	174.39 million	Optionable

DRUG, XERS, CMPS, and OCUL Headlines

Recent News About These Companies

Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $250,000.00 in Stock

2 hours ago | insidertrades.com

Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports

September 29 at 11:35 PM | finance.yahoo.com

Xeris Biopharma reportedly draws takeover interest — but firm says it’s not for sale

September 29 at 11:35 PM | msn.com

Xeris Biopharma (NASDAQ:XERS) Insider Sells 25,000 Shares of Stock

September 29 at 7:07 PM | marketbeat.com

Lundbeck expresses interest in buying Xeris, Bloomberg News reports

September 29 at 1:33 PM | marketscreener.comM

Xeris Biopharma jumps on report of interest from H Lundbeck

September 29 at 1:33 PM | msn.com

Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High - What's Next?

September 29 at 12:40 PM | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Shares Up 5.2% - Here's What Happened

September 28 at 2:39 PM | marketbeat.com

1,397,050 Shares of Xeris Biopharma Holdings, Inc. $XERS Acquired by Bank of America Corp DE

September 27 at 3:11 AM | marketbeat.com

Corient Private Wealth LP Acquires 184,126 Shares of Xeris Biopharma Holdings, Inc. $XERS

September 26, 2026 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of "Hold" by Analysts

September 21, 2026 | marketbeat.com

Xeris Biopharma stock gains on higher targets and August results

September 19, 2026 | ad-hoc-news.deA

Xeris Biopharma (NASDAQ:XERS) Upgraded to "Buy" at Wall Street Zen

September 19, 2026 | americanbankingnews.com

Wall Street Zen Upgrades Xeris Biopharma (NASDAQ:XERS) to Buy

September 19, 2026 | marketbeat.com

Xeris Biopharma Holdings stock gains after strong Q2 revenue growth

September 18, 2026 | ad-hoc-news.deA

Squarepoint Ops LLC Has $2.90 Million Holdings in Xeris Biopharma Holdings, Inc. $XERS

September 14, 2026 | marketbeat.com

Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy - Slideshow

September 11, 2026 | seekingalpha.com

Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript

September 9, 2026 | seekingalpha.com

Xeris Biopharma (NASDAQ:XERS) Trading Down 8.7% - Time to Sell?

September 9, 2026 | marketbeat.com

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

September 9, 2026 | finance.yahoo.com

Wellington Management Group LLP Acquires 193,749 Shares of Xeris Biopharma Holdings, Inc. $XERS

September 7, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DRUG, XERS, CMPS, and OCUL Company Descriptions

Compass Pathways NASDAQ:CMPS

$12.96 -0.27 (-2.04%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$13.07 +0.11 (+0.86%)

As of 07:14 AM Eastern

Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Bright Minds Biosciences NASDAQ:DRUG

$49.74 -1.92 (-3.72%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$50.00 +0.26 (+0.52%)

As of 04:02 AM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Ocular Therapeutix NASDAQ:OCUL

$7.87 +0.21 (+2.74%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$7.84 -0.03 (-0.38%)

As of 07:17 AM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Xeris Biopharma NASDAQ:XERS

$9.98 +0.15 (+1.53%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$9.99 +0.01 (+0.10%)

As of 07:19 AM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DRUG, XERS, CMPS, and OCUL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DRUG, XERS, CMPS, and OCUL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DRUG, XERS, CMPS, and OCUL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DRUG, XERS, CMPS, and OCUL Company Descriptions

Compass Pathways NASDAQ:CMPS

Bright Minds Biosciences NASDAQ:DRUG

Ocular Therapeutix NASDAQ:OCUL

Xeris Biopharma NASDAQ:XERS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DRUG, XERS, CMPS, and OCUL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DRUG, XERS, CMPS, and OCUL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DRUG, XERS, CMPS, and OCUL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DRUG, XERS, CMPS, and OCUL Company Descriptions

Compass Pathways NASDAQ:CMPS

Bright Minds Biosciences NASDAQ:DRUG

Ocular Therapeutix NASDAQ:OCUL

Xeris Biopharma NASDAQ:XERS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools